Hypersexuality Due to Adverse Effects of Medicines and Surgical Interventions
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The article reports on various pharmacological drugs, the side effects of which can lead to hypersexuality. In addition, observations are given when it was a side effect of surgical interventions.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Глубокая стимуляция головного мозга (DBS). Характеристика метода и его применение. – URL: https://golos.io/ru--mediczina/@medicalinfo/glubokaya-stimulyaciya-golovnogomozga-dbs-kharakteristika-metodai-ego-primenenie (дата обращения: 06.05.2019).
Кочарян Г.С. Гиперсексуальность. – Харьков: ДИСА ПЛЮС, 2020. – 263 с.
Никитина А.В., Федорова Н.В. Импульсивно-компульсивный синдром при болезни Паркинсона // Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (Выпуск 2. Неврология и психиатрия пожилого возраста). – 2013. – 113 (7). – С. 32–38.
Baird A.D., Wilson S.J., Bladin P.F., Saling M.M., Reutens D.C. Hypersexuality after Temporal Lobe Resection // Epilepsy & Behavior. – 2002. – 3 (2). – P. 173–181.
Barake M., Klibanski A., Tritos N.A. MANAGEMENT OF ENDOCRINE DISEASE: Impulse control disorders in patients with hyperpolactinemia treated with dopamine agonists: how much should we worry? // Eur J Endocrinol. – 2018. – 179 (6). – R287–R296. DOI: 10.1530/EJE-18-0667.
Bayard S., Cochen De Cock V., Dauvillers Y. [Dopamine dysregulation syndrome in Parkinson’s disease and restless legs syndrome]. [Article in French] // Geriatr Psychol Neuropsychiatr Vieil. – 2011. – 9 (2). – P. 227–235. DOI: 10.1684/pnv.2011.0275.
Berger Ch., Mehrhoff F.W., Beier K.M., Meinck H.M. [Sexual delinquency and Parkinson’s disease] [Article in German] // Nervenarzt. – 2003. – 74 (4). – P. 370–375.
Berk M., Acton M. Citalopram-associated clitoral priapism: a case series // Int Clin Psychopharmacol. – 1997. – 12 (2). – P. 121–122.
Bhattacharjee S. Impulse control disorders in Parkinson’s disease: Review of pathophysiology, epidemiology, clinical features, management, and future challenges // Neurol India. – 2018. – 66 (4). – P. 967–975. DOI: 10.4103/0028-3886.237019.
Bronner G., Vodušek D.B. Management of sexual dysfunction in Parkinson’s disease // Ther Adv Neurol Disord. – 2011. – 4 (6). – P. 375–383. DOI: 10.1177/1756285611411504.
Bronner G., Royter V., Korczyn A.D., Giladi N. Sexual Dysfunction in Parkinson’s Disease // J Sex Marital Ther. – 2004. – 30 (2). – P. 95–105. DOI: 10.1080/00926230490258893.
Chatzittofis A., Arver S., Öberg K., Hallberg J., Nordström P., Jokinen J. HPA axis dysregulation in men with hypersexual disorder // Psychoneuroendocrinology. – 2016. – 63. – P. 247–253. DOI: 10.1016/j.psyneuen.2015.10.002.
Chollet C.A., Andreatini R. Effect of bupropion on sexual dysfunction induced by fluoxetine: a case report of hypersexuality // J Clin Psychiatry. – 2003. – 64 (10). – P. 1268–1269.
Das P., Rai A., Chopra A., Dewan V. Sertraline-induced hypersexuality in a patient taking bupropion // Prim Care Companion CNS Disord. – 2012. – 14 (2). pii: PCC.11l01232. DOI: 10.4088/PCC.11l01232.
Devinsky J., Sacks O., Devinsky O. Kluver-Bucy syndrome, hypersexuality, and the law // Neurocase. – 2010. – 16 (2). – P. 140–145. DOI: 10.1080/13554790903329182.
Ellison J.M. Exercise-induced orgasms associated with fluoxetine treatment of depression // J Clin Psychiatry. – 1996. – 57 (12). – P. 596–597.
Elmore J.L., Quattlebaum J.T. Female sexual stimulation during antidepressant treatment // Pharmacotherapy. – 1997. – 17 (3). – P. 612–616.
Ferrara J.M., Stacy M. Impulsive controle disorders and Parkinson’s disease // CNS Spectr. – 2008. – 13 (8). – P. 690–698.
Garcia-Campayo J., Sanz-Carrillo C., Lobo A. Orgasmic sexual experiences as a side effect of fluoxetine: a case report // Acta Psychiatr Scand. – 1995. – 91 (1). – P. 69–70.
Garcia-Ruiz P.J. Impulse Control Disorders and Dopamine-Related Creativity: Pathogenesis and Mechanism, Short Review, and Hypothesis // Front Neurol. – 2018. – 9. – P. 1041. DOI: 10.3389/fneur.2018.01041.
Gilbert F. The burden of normality: from ‘chronically ill’ to ‘symptom free’. New ethical challenges for deep brain stimulation postoperative treatment // J Med Ethics. – 2012. – 38 (7). – P. 408–412. DOI: 10.1136/medethics-2011-100044.
Girard R., Obeso I., Thobois S., Park S.A., Vidal T., Favre E.., Ulla M., Broussolle E.., Krack P., Durif F., Dreher J.C. Wait and you shall see: sexual delay discounting in hypersexual Parkinson’s disease // Brain. – 2019. – 142 (1). – P. 146–162. DOI: 10.1093/brain/awy298.
Hanada H., Akiyoshi J., Kanehisa M., Ishitobi Y., Tsuru J., Tanaka Y., Shimomura T., Kawano Y. Hippocampal Agenesis in an Individual who Engaged in Violent Criminal Behaviors After Discontinuing Carbamazepine and Paroxetine Treatment // J Forensic Sci. – 2013. – 58 (1). – P. 255–258. DOI: 10.1111/j.1556-4029.2012.02248.x.
Hypersexuality – Explaining the Medical Condition Behind It. – URL: http://www.womenhealthzone.com/womenshealth/sexuality/hypersexuality / (the date of the reference: 03.02.2020).
Hypersexuality. – URL: https://en.wikipedia.org/wiki/Hypersexuality (the date of the reference: 02.03.2019).
Kelley B.J., Duker A.P., Chiu P. Dopamine agonists and pathologic behaviors // Parkinsons Dis. 2012;2012:603631. DOI: 10.1155/2012/603631.
Kitaichi Y.., Inoue T., Nakagawa S., Boku S., Kakuta A., Izumi T., Koyama T. Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats // Eur J Pharmacol. – 2010. – 647 (1–3). – P. 90–96.
Klos K.J., Bower J.H., Josephs K.A., Matsumoto J.Y., Ahlskog J.E. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson’s disease and multiple system atrophy // Parkinsonism & related disorders. – 2005. – 11 (6). – P. 381–386.
Kraus Shane W., Voon Valerie, Potenza Marc N. Should compulsive sexual behavior be considered an addiction? // Addiction. – 2016. – 111 (12). – P. 2097–2106.
Leeman R.F., Potenza M.N. Impulse control disorders in Parkinson’s disease: clinical characteristics and implications // Neuropsychiatry. – 2011. – 1 (2). – P. 133–147.
Martinkova J., Trejbalova L., Sasikova M., Benetin J., Valkovic P. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas // Clin Neuropharmacol. – 2011. – 34 (5). – P. 179–181. DOI: 10.1097/WNF.0b013e3182281b2f.
Mendez M.F., O’Connor S.M., Lim G.T. Hypersexuality after right pallidotomy for Parkinson’s disease // J Neuropsychiatry Clin Neurosci. – 2004. – 16 (1). – P. 37–40. https://doi.org/10.1176/jnp.16.1.37
Metin S.Z., Ozmen M., Ozkara C., Ozmen E. Hypersexuality in a patient with epilepsy during treatment of levetiracetam // Seizure. – 2013. – 22 (2). – P. 151–152. DOI: 10.1016/j.seizure.2012.11.002.
Modell J.G. Repeated observations of yawning, clitoral engorgement, and orgasm associated with fluoxetine administration // J Clin Psychopharmacol. – 1989. – 9 (1). – P. 63–65.
Molde H., Moussavi Y., Kopperud S. T., Erga A. H., Hansen A. L., Pallesen S. Impulse-Control Disorders in Parkinson’s Disease: A Meta-Analysis and Review of Case-Control Studies // Front Neurol. – 2018. – 9. – P. 330. DOI: 10.3389/fneur.2018.00330.
Morris P. L. Fluoxetine and orgasmic sexual experiences // Int J Psychiatry Med. – 1991. – 21 (4). – P. 379–382.
Moscovitch A., Blashko C. A., Eagles J. M., Darcourt G., Thompson C., Kasper S., Lane R. M. International Collaborative Group on Sertraline in the Treatment of Outpatients with Seasonal Affective Disorders. A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder // Psychopharmacology (Berl). – 2004. – 171 (4). – P. 390–397.
O’Sullivan S. S., Evans A. H., Lees A. J. Dopamine Dysregulation syndrome: an overview of its epidemiology, mechanism and management // CNS Drugs. – 2009. – 23 (2). – P. 157–170.
Oei N. Y., Rombouts S. A., Soeter R. P., van Gerven J. M., Both S. Dopamine modulates reward system activity during subconscious processing of sexual stimuli // Neuropsychopharmacology. – 2012. – 37 (7). – P. 1729–1737. DOI: 10.1038/npp.2012.19.
Pontone G., Williams J. R., Bassett S. S., Marsh L. Clinical features associated with impulse control disorders in Parkinson’s disease // Neurology. – 2006. – 67(7). – P. 1258–1261.
Prabhakar D., Balon R. How do SSRIs cause sexual dysfunction? // Current Psychiatry. – 2010. – 9. – P. 30–34.
Raja M., Bentivoglio A. R. Impulsive and compulsive behaviors during dopamine replacement treatment in Parkinson’s Disease and other disorders // Curr Drug Saf. – 2012. – 7 (1). – P. 63–75.
Roane D. M., Yu M., Feinberg T. E., Rogers J. D. Hypersexuality after pallidal surgery in Parkinson disease // Neuropsychiatry, neuropsychology, and behavioral neurology. – 2002. – 15 (4). – P. 247–251.
Schreglmann S. R., Gantenbein A. R., Eisele G., Baumann C. R. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome // Parkinsonism Relat Disord. – 2012. – 18 (2). – P. 207–209. DOI: 10.1016/j.parkreldis.2011.10.010.
Series Hugh, Dégano Pilar. Hypersexuality in dementia // Advances in Psychiatric Treatment. – 2005. – 11(6). – P. 424–431. https://doi.org/10.1192/apt.11.6.424
Shaw P., Blockley A., Clough C., Chaudhuri R., Weeks R., David A. S. Hypersexuality and Parkinson’s disease // J Neurol Neurosurg Psychiat. – 2003. – 74 (6). – P. 834.
Stahl S. M. Stahl’s Essential Psychopharmacology. 3rd ed. – New York, NY: Cambridge University Press, 2008. – 1132 p.
Thomson S. R , Patil N., Ommurugan B., Bhandary R. K. A Case of Hyper Sexuality Probably Associated with Clozapine // Psychopharmacol Bull. – 2018. – 48(4). – P. 20–24.
van Deelen R. A., Rommers M. K., Eerenberg J. G., Egberts A. C. [Hypersexuality during use of levodopa] [Article in Dutch] // Ned Tijdschr Geneeskd. – 2002. – 146 (44). – P. 2095–2098.
Vilas D., Pont-Sunyer C., Tolosa E. Impulse control disorders in Parkinson’s disease // Parkinsonism Relat Disord. – 2012 – 18 (Suppl 1). – P. 80–84. DOI: 10.1016/S1353-8020(11)70026-8.
Voon V. Repetition, repetition, and repetition: Compulsive and punding behaviors in Parkinson’s disease // Mov Disord. – 2004. – 19 (4). – P. 367–370.
Voon V., Hassan K., Zurowski M., de Souza M., Thomsen T., Fox S., Lang A. E., Miyasaki J. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease // Neurology. – 2006. – 67(7). – P. 1254–1257.
Weintraub D., Koester J., Potenza M. N., Siderowf A. D., Stacy M., Voon V., Whetteckey J., Wunderlich G. R., Lang A. E. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients // Archives of neurology. – 2010. – 67 (5). – P. 589–595.
Weintraub D., Siderowf A. D., Potenza M. N., Goveas J., Morales K. H., Duda J. E., Moberg P. J., Stern M. B. Association of dopamine agonist use with impulsive control disorders in Parkinson’s disease // Arch Neurol. – 2006. – 63 (7). – P. 969–973.
